Ketamine Usage Effectivity on Treatment-Resistant Depression Diagnosed Patients: a Scoping Review
Satrio Wahyu Nugroho, Agustina Konginan, Gadis Meinar Sari, Erikavitri Yulianti
Jurnal Psikiatri Surabaya May 13, 2024 Peer reviewed DOI: 10.20473/jps.v13i1.34068 via DOAJ
Summary
Ketamine is more effective than placebo in reducing depressive symptoms in adults with treatment-resistant depression (TRD), particularly at doses of 0.4 mg/kg and 0.5 mg/kg. In elderly patients, doses above 0.2 mg/kg are effective, with the maximal effect observed 24 hours after administration, lasting about 7 days. Repeated ketamine treatments may enhance the chances of remission for TRD patients.
Study at a glance
| Design | retrospective observational study |
|---|---|
| Population | patients diagnosed with treatment-resistant depression |
| Key finding | Ketamine therapy is more effective than placebo in reducing depressive symptoms in patients diagnosed with treatment-resistant depression. |
Abstract
Introductions: In Indonesia, a median of 6.1% of people diagnosed with depression disorder are people over 15 years old. Only 9% of that amount underwent medical treatment, while the rest, 91%, did not undergo treatment for their depressive conditions. Inadequate and inappropriate treatment of depression will lead to Treatment-Resistant Depression (TRD). Using ketamine as a pharmacotherapy opens up new possibilities for TRD treatments. Methods: This study uses a retrospective observational study design with a systematic review approach, in which all variable data were collected from previous studies aimed at measuring the effectiveness of ketamine pharmacological therapy in patients diagnosed with treatment-resistant depression (TRD) using placebo as a benchmark of the effectiveness of ketamine in reduced clinical symptoms of TRD using secondary data in the form of study results and analyzes from published studies of the effectiveness of ketamine therapy. Results: Administration of ketamine at doses of 0.4 mg/kg and 0.5 mg/kg is more effective as an antidepressant compared to placebo in adults and is effective in the elderly at doses above 0.2 mg/kg with a maximal effect at 24 hours post-administration and disappeared by about 7 days post-administration. Conclusions: The administration of ketamine therapy is more effective at reducing depressive symptoms in diagnosed patients (TRD) than the use of placebo and repeated administration of ketamine can increase the likelihood that TRD sufferers respond to therapy and experience remission.